title: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
abstract: OBJECTIVE
  To compare mantle-cell lymphomas (MCLs) and follicle-center lymphomas (FCLs) for their features of clinical presentation, response to chemotherapy, and prognosis on the basis of a prospective randomized clinical trial.
  
  
  METHODS
  Patients with MCL and FCL who entered onto the prospective randomized comparison of cyclophosphamide, vincristine, and prednisone (COP) versus prednimustine and mitoxantrone (PmM) followed by a second randomization for interferon (IFN) maintenance versus observation only.
  
  
  RESULTS
  One hundred sixty-five of 234 patients had FCL and 45 of 234 patients had MCL. With FCL, both sexes were equally affected (men, 47%); patients with MCL were predominantly men (78%; P < .0004) and had a higher median age (64 v 53 years; P < .0001). Patients with MCL also had more widespread disease, reflected by the proportion of patients with two or greater extranodal manifestations (43% v 21%; P < .005) and nine or greater involved nodal areas (64% v 45%; nonsignificant [NS]). Response to chemotherapy was significantly lower in patients with MCL (complete remission [CR] + partial remission [PR], 69% v 88%; P < .05) and occurred at a slower pace. Patients with MCL also had a shorter event-free interval (median, 8 v 24 months; P < .0001) and overall survival (median, 28 v 77 months; P < .0001). In both subtypes, however, patients with less than two residual lymphoma manifestations in remission experienced a relatively good prognosis with an estimated 5-year survival of greater than 60% for MCL and greater than 75% for FCL.
  
  
  CONCLUSIONS
  MCL and FCL differ substantially in their features of presentation, response to chemotherapy, and long-term prognosis. The extent of residual disease after completion of chemotherapy discriminates patients with different prognosis and may be used for the stratification of postremission strategies.
authors.affiliation: Department of Hematology and Oncology, University of Göttingen, Germany. whiddema@univ.goettingen.de
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: M
authors.initials: M
authors.lastname: Unterhalt
authors.forename: R
authors.initials: R
authors.lastname: Herrmann
authors.forename: H H
authors.initials: HH
authors.lastname: Wöltjen
authors.forename: E D
authors.initials: ED
authors.lastname: Kreuser
authors.forename: L
authors.initials: L
authors.lastname: Trümper
authors.forename: M
authors.initials: M
authors.lastname: Reuss-Borst
authors.forename: E
authors.initials: E
authors.lastname: Terhardt-Kasten
authors.forename: M
authors.initials: M
authors.lastname: Busch
authors.forename: A
authors.initials: A
authors.lastname: Neubauer
authors.forename: U
authors.initials: U
authors.lastname: Kaiser
authors.forename: R D
authors.initials: RD
authors.lastname: Hanrath
authors.forename: H
authors.initials: H
authors.lastname: Middeke
authors.forename: G
authors.initials: G
authors.lastname: Helm
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: H
authors.initials: H
authors.lastname: Stein
authors.forename: M
authors.initials: M
authors.lastname: Tiemann
authors.forename: R
authors.initials: R
authors.lastname: Parwaresch
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011238:Prednimustine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D011238:Prednimustine; D008942:Mitoxantrone; D011241:Prednisone